Literature DB >> 2877011

Infection of human T lymphotropic virus-I-specific immune T cell clones by human T lymphotropic virus-I.

H Mitsuya, R F Jarrett, J Cossman, O J Cohen, C S Kao, H G Guo, M S Reitz, S Broder.   

Abstract

Human T lymphotropic virus-I (HTLV-I)-specific T cell lines were established and cloned. K5, an OKT8+ clone bearing multiple proviral integration sites, retained its HTLV-I-specific cytotoxicity and a normal dependence on interleukin 2 (IL-2), indicating that there is a finite number of transforming integration sites. R2, an OKT4+ HTLV-I-infected clone, initially mounted a proliferative response to HTLV-I; but then its IL-2-independent proliferation increased and the antigen specificity was lost. All HTLV-I-infected clones tested including K7, another OKT8+ transformed cytotoxic clone that had lost its reactivity, expressed comparable levels of T cell receptor beta-chain (TCR-beta) messenger (m)RNA. Although clones K5 and K7 had different functional properties, they had the same rearrangement of the TCR-beta gene, suggesting that they had the same clonal origin. These data indicate that HTLV-I-specific T cells retain their immune reactivity for variable periods of time following infection, but then usually lose it; in some cases, however, no alteration in function can be detected. The data also suggest that different consequences can take place in the same clone depending on the pattern of retroviral infection.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2877011      PMCID: PMC423817          DOI: 10.1172/JCI112715

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  52 in total

1.  Effect of adult T-cell leukemia cells on pokeweed mitogen-induced normal B-cell differentiation.

Authors:  T Uchiyama; K Sagawa; K Takatsuki; H Uchino
Journal:  Clin Immunol Immunopathol       Date:  1978-05

2.  Letter: Two cases of T-cell chronic lymphocytic leukemia in Japan.

Authors:  J Yodoi; K Takatsuki; T Masuda
Journal:  N Engl J Med       Date:  1974-03-07       Impact factor: 91.245

3.  Isolation and partial nucleotide sequence of a cDNA clone for human histocompatibility antigen HLA-B by use of an oligodeoxynucleotide primer.

Authors:  A K Sood; D Pereira; S M Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  1981-01       Impact factor: 11.205

4.  A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells.

Authors:  T Uchiyama; S Broder; T A Waldmann
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

5.  Chronic immune stimulation is required for Moloney leukaemia virus-induced lymphomas.

Authors:  J C Lee; J N Ihle
Journal:  Nature       Date:  1981-01-29       Impact factor: 49.962

6.  Immunological properties of a type C retrovirus isolated from cultured human T-lymphoma cells and comparison to other mammalian retroviruses.

Authors:  V S Kalyanaraman; M G Sarngadharan; B Poiesz; F W Ruscetti; R C Gallo
Journal:  J Virol       Date:  1981-06       Impact factor: 5.103

7.  Characterization and distribution of nucleic acid sequences of a novel type C retrovirus isolated from neoplastic human T lymphocytes.

Authors:  M S Reitz; B J Poiesz; F W Ruscetti; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1981-03       Impact factor: 11.205

8.  Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.

Authors:  B J Poiesz; F W Ruscetti; A F Gazdar; P A Bunn; J D Minna; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

9.  Configuration and expression of the T cell receptor beta chain gene in human T-lymphotrophic virus I-infected cells.

Authors:  R F Jarrett; H Mitsuya; D L Mann; J Cossman; S Broder; M S Reitz
Journal:  J Exp Med       Date:  1986-02-01       Impact factor: 14.307

10.  Detection of the human T cell lymphoma virus p19 in cells of some patients with cutaneous T cell lymphoma and leukemia using a monoclonal antibody.

Authors:  M Robert-Guroff; F W Ruscetti; L E Posner; B J Poiesz; R C Gallo
Journal:  J Exp Med       Date:  1981-12-01       Impact factor: 14.307

View more
  7 in total

Review 1.  Viral modulation of T-cell receptor signaling.

Authors:  Keith R Jerome
Journal:  J Virol       Date:  2008-02-20       Impact factor: 5.103

2.  PolyI.polyC12U-mediated inhibition of loss of alloantigen responsiveness viral replication in human CD4+ T cell clones exposed to human immunodeficiency virus in vitro.

Authors:  J Laurence; J Kulkosky; S M Friedman; D N Posnett; P O Ts'o
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

3.  Pharmacological inhibition of in vitro infectivity of human T lymphotropic virus type I.

Authors:  S Matsushita; H Mitsuya; M S Reitz; S Broder
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

4.  Modulation of T-cell responses to a recall antigen in human T-cell leukemia virus type 1-infected individuals.

Authors:  M Suzuki; C S Dezzutti; A Okayama; N Tachibana; H Tsubouchi; N Mueller; R B Lal
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

5.  Evolutionary insights on the origin of human T-cell lymphoma/leukemia virus type I (HTLV-I) derived from sequence analysis of a new HTLV-I variant from Papua New Guinea.

Authors:  M P Sherman; N K Saksena; D K Dube; R Yanagihara; B J Poiesz
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

6.  Human T-cell leukemia virus type I infection of CD4+ or CD8+ cytotoxic T-cell clones results in immortalization with retention of antigen specificity.

Authors:  D V Faller; M A Crimmins; S J Mentzer
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

7.  HTLV-1 drives vigorous clonal expansion of infected CD8(+) T cells in natural infection.

Authors:  Anat Melamed; Daniel J Laydon; Hebah Al Khatib; Aileen G Rowan; Graham P Taylor; Charles R M Bangham
Journal:  Retrovirology       Date:  2015-11-09       Impact factor: 4.602

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.